CBD for Endometriosis – What the Science Says 2026

Endometriosis affects about 10% of women of reproductive age worldwide, which in Poland translates to an estimated 2-3 million patients (ESHRE Endometriosis Guideline, 2022). The average delay in diagnosis in Europe is 7-10 years, and many women visit a gynecologist after years of chronic pelvic pain, dysmenorrhea, and mental exhaustion. It is no surprise that patients turn to anything that helps them get through the day.

In this context, the question of CBD arises. Does cannabidiol really help with endometriosis, or is it just another empty promise? Scientifically, the truth lies somewhere in the middle. There are survey studies, preclinical data, and analyses of the endocannabinoid system (ECS) that suggest potential symptomatic support. However, there is a lack of large randomized clinical trials that would provide a definitive answer.

In this article, we organize the facts according to the current knowledge of 2026. We cite Sinclair 2021, Andrieu 2022, Reinert 2023, Barlow 2018, and Sanchez Quesada 2018. We show where CBD can realistically help and where it falls short and cannot replace a gynecologist. The text is scientifically empathetic, not marketing-driven. Endometriosis is serious, so the approach must be serious.

Key findings
– Endometriosis is a chronic disease that requires treatment by a gynecologist, including laparoscopic diagnosis and individual hormonal therapy (ESHRE, 2022).
– CBD is a symptomatic support, not a causal therapy – it does not remove the foci and does not stop the progression of the disease.
– The data is promising but preliminary. Sinclair 2021 (n=484) reports subjective pain reduction in the majority of women using cannabis, but no large RCTs have been reported.
– The typical dosage range in clinical work is 25-50 mg of CBD per day, divided into 2-3 doses, sublingual form (Andrieu, 2022).
– Always coordinate CBD with your healthcare provider, especially if you are using hormonal contraception, dienogest, GnRH, or are planning surgery.

What is endometriosis according to the ESHRE definition?

Endometriosis is a chronic, estrogen-dependent inflammatory disease in which tissue histologically similar to the endometrium occurs outside the uterine cavity (ESHRE Endometriosis Guideline, 2022). The disease affects about 10% of women of reproductive age, which globally amounts to approximately 190 million people (WHO, 2023). The spectrum of symptoms is very wide, ranging from asymptomatic cases to extremely debilitating pelvic pain.

We most commonly encounter three clinical forms. Peritoneal endometriosis involves superficial lesions on the pelvic peritoneum. Endometrial cysts (endometriomas) are located on the ovaries. Deep infiltrating endometriosis (DIE) penetrates more than 5 mm beneath the peritoneum and may involve the intestines, bladder, and rectovaginal septum. Each form presents a slightly different symptom profile and requires a different treatment strategy.

The pathophysiology is multifactorial. The most popular Sampson theory assumes retrograde menstruation with the implantation of endometrial cells in abnormal locations. Nowadays, immunological, hormonal, genetic, and neuroangiogenic mechanisms are also considered. This is why endometriosis is now understood as a systemic disease, not just a pelvic one.

What symptoms does endometriosis cause?

The first signal is often dysmenorrhea, or severe menstrual pain that does not subside after standard NSAIDs. There is also chronic pelvic pain outside of menstruation, dyspareunia (pain during intercourse), dyschezia (pain during bowel movements), and dysuria. In some patients, the leading issue is infertility. Endometriosis accounts for 30-50% of female infertility cases (PubMed, 2021).

Symptoms often extend beyond the pelvic floor. Exhaustion, cognitive fog, sleep disturbances, anxiety, and depression are significantly more common than in the general population. These are not "psychogenic" complaints, but rather a consequence of chronic pain and systemic inflammation. Understanding this context is crucial when discussing CBD as a potential support.

Why does diagnosis take so long?

The average delay in diagnosing endometriosis is 7-10 years (ESHRE, 2022). There are several reasons. Menstrual pain in teenagers is often not taken seriously for a long time. An ultrasound image may be normal despite active disease. The gold standard for diagnosis, which is laparoscopy with biopsy, is an invasive procedure. Therefore, diagnosis often comes after many consultations.

Endometriosis is a chronic estrogen-dependent inflammatory disease affecting about 10% of women of reproductive age. The average delay in diagnosis is 7-10 years, and the gold standard for diagnosis remains laparoscopy with histopathological verification (ESHRE Guideline, 2022).

How does the endocannabinoid system work in the endometrium?

The endocannabinoid system (ECS) is physiologically present in the female endometrium and plays a role in the menstrual cycle, decidualization, and embryo implantation (Barlow et al., Reprod Sci, 2018). In the tissues of patients with endometriosis, the expression of CB1 and CB2 receptors is altered, suggesting ECS dysfunction as an element of pathogenesis. Sanchez Quesada 2018 described a decrease in CB1 activity in deep endometrial lesions.

ECS is a system that regulates homeostasis. It consists of receptors (mainly CB1 and CB2), endogenous ligands (anandamide AEA, 2-AG), and degrading enzymes (FAAH, MAGL). The CB1 receptor predominates in the central nervous system and modulates pain perception. CB2 is found on immune cells and plays a key role in regulating inflammation.

In healthy endometrium, the expression of CB1 and CB2 changes cyclically with the menstrual phase. Anandamide reaches its highest concentration during the ovulatory phase. In endometriosis, dysregulation of these dynamics is observed. Changes affect both the lesions themselves and the normal endometrium of patients with the disease. This is an important biological argument for the potential of ECS modulation.

What specifically does Barlow 2018 show?

Barlow and co-authors in a 2018 review in Reproductive Sciences gathered data on the role of ECS in the endometrium. Anandamide participates in regulating the proliferation of endometrial cells, decidualization, and the implantation process. Changes in CB1 expression affect uterine motility and embryo transport. ECS dysregulation may participate in the pathogenesis of recurrent miscarriages and endometriosis (Reprod Sci, 2018).

In practice, this translates into the "endocannabinoid deficiency" hypothesis. Some researchers propose that some chronic diseases, including endometriosis, fibromyalgia, and migraine, have a common denominator in the form of ECS failure (PubMed, 2016). The hypothesis is not proven but provides a coherent interpretative framework for many clinical observations.

Sanchez Quesada 2018 and receptor expression

Sanchez Quesada et al. published a molecular analysis of endometrial tissues from patients with endometriosis and a control group in 2018. They demonstrated changes in cannabinoid receptor expression in deep infiltrating lesions, including reduced CB1 and changes in the activity of enzymes that degrade endocannabinoids (Mol Cell Endocrinol, 2018). This provides a biological rationale for why ECS modulation may make sense as a symptomatic strategy.

Unique observation: The ECS in endometriosis is like a home's temperature-regulating system with a faulty thermostat. The receptors are present, but their expression is "mistuned" to the tissue's needs. CBD won't fix the thermostat, but it can stabilize pain sensations and inflammation around this dysfunction. Therefore, the effect is symptomatic, not structural.

How does CBD affect pain and inflammation?

CBD is not a classical agonist of cannabinoid receptors. It acts through multiple molecular targets, including indirect modulation of CB1 and CB2, agonism of the 5-HT1A receptor, modulation of TRPV1, and inhibition of the FAAH enzyme, which prolongs the action of endogenous anandamide (Frontiers in Pharmacology, 2020). In the context of endometriosis, the most significant effects are anti-inflammatory and modulation of pain transmission.

The anti-inflammatory action of CBD has been confirmed in many preclinical models. CBD reduces the expression of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta), decreases NF-kB activity, and reduces macrophage accumulation in tissues. Reinert 2023 reviews these mechanisms in the context of painful-inflammatory diseases of the pelvis (PubMed, 2023).

In the context of visceral pain, typical for endometriosis, CBD modulates the TRPV1 receptor present on afferent nerve fibers. TRPV1 is activated by prostaglandins and heat, and its modulation by CBD may reduce the transmission of pain signals to the brain. This is a different mechanism than classical NSAIDs, so the effect may be additive with ibuprofen.

Why CBD and not THC?

THC is a strong agonist of CB1 and produces psychoactive effects. In Poland, products with THC above 0.3% are illegal, and the descriptions of THC's side effects (anxiety, paranoia, cognitive disturbances) exclude it as a first-line therapy for chronic conditions. CBD is non-psychoactive and well-tolerated in doses up to 1500 mg per day according to a WHO review from 2018.

Some studies suggest that small amounts of THC are needed for the full clinical effect in the presence of CBD (the entourage effect). In Polish practice, this means choosing full-spectrum oils within the permissible limit of 0.3% THC or a safer broad-spectrum option without THC. For patients working in drug testing professions, broad-spectrum is recommended.

CB2 receptor as a key target

CB2 predominates on immune system cells (T lymphocytes, macrophages, dendritic cells). Its activation reduces the production of pro-inflammatory cytokines and inhibits the migration of leukocytes to the site of inflammation. In endometriosis, the immune infiltration around the lesions is one of the main sources of chronic pain (Front Reprod Health, 2022).

CBD activates CB2 indirectly and through allosteric modulation. This is a gentler action than classical agonism, but sufficient to reduce inflammation in the endometrium in preclinical models. The full mechanistic picture in humans is not yet resolved, so we should treat this data as a direction, not a certainty.

CBD acts anti-inflammatorily through indirect modulation of CB1/CB2 receptors, agonism of 5-HT1A, and inhibition of FAAH, which prolongs the action of endogenous anandamide. In preclinical models, CBD reduces the expression of TNF-alpha and IL-6 and decreases macrophage accumulation (Frontiers in Pharmacology, 2020).

What do clinical studies say about CBD and endometriosis?

The three most cited sources are often mentioned. Sinclair 2021 is an online survey involving 484 women with confirmed endometriosis, published in the Journal of Obstetrics and Gynaecology Canada. Andrieu 2022 is a review article in Frontiers in Reproductive Health. Reinert 2023 discusses cannabinoids in pelvic pain. All indicate potential but also a low level of evidence.

In the Sinclair survey (J Obstet Gynaecol Can, 2021), most respondents reported subjective improvement after using cannabis (both THC and CBD products). The most common effects were reduction of pelvic pain, better sleep, and decreased nausea. Limitations: survey study, selection bias, lack of a control group and randomization.

Andrieu and co-authors (Front Reprod Health, 2022) gathered available pharmacological and clinical data, focusing on the mechanisms of action of cannabinoids in endometriosis. They point to the rationale for ECS modulation and the potential of CBD as an adjunct to pain therapy, but they clearly emphasize the need for randomized clinical trials with a placebo group.

What specifically do the numbers from Sinclair 2021 show?

Of the 484 respondents, 95% reported that cannabis reduced their pain. The average symptom severity decreased from about 7.6 to 3.4 points on a 10-point scale. The most common forms of use were vaporizing flowers (54%) and oral oils (38%). 56% of respondents reduced doses of other medications after introducing cannabis. These are very encouraging numbers, but it is still a survey, not an RCT.

What does this mean in practice? That a large group of women with endometriosis subjectively feels relief. However, we do not know how much of this effect is placebo, how much is selection bias (because mainly those who were helped by CBD responded), and how much is the actual pharmacology of cannabinoids. Scientifically, this is hypothesis-generating data, not confirmatory.

Reinert 2023 and pelvic pain

Reinert and co-authors in a 2023 review discuss the use of cannabinoids in chronic pelvic pain, including endometriosis and painful bladder syndrome. Conclusion: the data is promising, but there is a lack of phase 3 studies, i.e., large randomized placebo-controlled trials (PubMed, 2023). Without this, CBD remains in the category of a "reasonable off-label option," not a standard of care.

What is lacking in the literature in 2026?

There is a lack of randomized clinical trials of CBD in endometriosis with a placebo group, validated endpoints (numerical pain scale, EHP-30 quality of life), and a minimum observation period of 12 weeks. There is a lack of data on long-term safety and effects on fertility. There are no head-to-head comparisons with dienogest, GnRH, or progesterone agonists.

From the perspective of the Bucha editorial office: In our store, we observe that customers diagnosed with endometriosis most often purchase 5% and 10% broad-spectrum oils. 25% is rarely chosen, despite the marketing trend of "more is better." This aligns with the literature, which suggests a "therapeutic window" for CBD around 25-50 mg per day. Higher doses do not produce proportionally better results.

What realistic effects can be expected from CBD?

Realistic effects of CBD for endometriosis include reduced pain intensity, improved sleep, reduced mental stress, and better tolerance of daily responsibilities. According to the 2021 Sinclair survey, the average subjective pain reduction was approximately 4.2 points out of 10. This does not mean complete relief of symptoms, but a shift from "disabling" to "tolerable" (J Obstet Gynaecol Can, 2021).

The first area of real improvement is sleep. CBD in doses of 25-50 mg in the evening often shortens the time to fall asleep and reduces the number of awakenings. This is crucial because sleep deprivation lowers the pain threshold and worsens mood. In endometriosis, sleep can be disrupted by nighttime complaints, so a good night's sleep translates to a better day.

The second area is background pain, or persistent pelvic pain outside of menstruation. Many patients describe it as "dull, tiring, and pervasive." CBD can reduce its intensity through its anti-inflammatory effects and TRPV1 modulation. The effect is rarely dramatic in the first week, increasing over 4-8 weeks of regular dosing.

What CBD is unlikely to do?

CBD is unlikely to eliminate acute episodic pain rated 9-10/10. In such episodes, NSAIDs (ibuprofen, ketoprofen, naproxen) or prescription tramadol act faster. CBD will also not reduce the size of an endometrioma on its own nor stop disease progression in a way that would replace hormonal therapy. It will not eliminate infertility related to endometriosis.

These are important caveats, as the internet is full of promises of "healing CBD." There are no magic pills for endometriosis, neither synthetic nor natural. Instead, there is teamwork (gynecologist, urogynecological physiotherapist, dietitian, and sometimes psychologist), in which CBD can be a helpful component. No more, no less.

Quality of life as an endpoint

In studies on endometriosis, the EHP-30 scale (Endometriosis Health Profile) is increasingly used, which measures the impact of the disease on daily functioning. Andrieu 2022 indicates that cannabinoids may improve EHP-30 scoring in the domains of pain, disease control, and social support (Front Reprod Health, 2022). This is a more practical endpoint than just a number on a pain scale.

In the Sinclair 2021 survey (n=484 women with endometriosis), 95% of respondents reported that cannabis reduced their pain, and the average symptom severity decreased from 7.6 to 3.4 points on a 10-point scale (J Obstet Gynaecol Can, 2021). These are survey data, not a randomized controlled trial, so they require confirmation in RCT.

What CBD WON'T do - the limits of the method

CBD will not replace laparoscopy or hormonal therapy. The ESHRE 2022 guidelines clearly indicate that the first line of pharmacological treatment for endometriosis consists of progestogens (dienogest), combined contraceptive preparations, and GnRH agonists, and surgical treatment (laparoscopy with removal of lesions) is the gold standard when pharmacotherapy is ineffective (ESHRE, 2022).

What exactly does it mean that CBD won't replace laparoscopy? A 4-cm endometrioma won't disappear with CBD oil, regardless of the dose. A lesion deeply infiltrating the intestine requires surgical evaluation. Infertility related to pelvic anatomy may require adhesiolytic surgery. Attempting to "treat" such situations with CBD delays proper medical intervention.

Hormonal therapy intentionally affects the hypothalamic-pituitary-ovarian axis. It limits the exposure of endometrial lesions to estrogens, slowing their activity. CBD does not have such central action. It does not change the levels of estradiol, progesterone, or LH/FSH in a way comparable to dienogest or GnRH agonists.

When is an urgent visit to the gynecologist needed?

Never delay a visit in case of acute abdominal pain of sudden onset, unexplained intermenstrual bleeding, fainting during menstruation, fever with pelvic pain, suspicion of ectopic pregnancy, or acute torsion of a cyst. These are conditions where CBD is absolutely inappropriate, and delay costs health.

Also, chronic pain that worsens despite treatment and new symptoms (rectal bleeding during menstruation, hematuria, unilateral pain radiating to the leg) are indications for urgent diagnostic reassessment. Endometriosis can progress and involve new locations, so regular follow-up with a gynecologist is crucial.

What about diet, physiotherapy, and other methods?

An anti-inflammatory diet (Mediterranean, reducing red meat, increasing omega-3 fatty acids) has moderate support in the literature. Urogynecological physiotherapy helps with pelvic floor muscle tension, which often accompanies endometriosis. Yoga, mindfulness, and cognitive-behavioral therapy reduce pain perception. CBD can be one of the elements of this package, not a monotherapy.

CBD category on ubucha.pl

How to practically dose CBD for endometriosis?

According to the literature and the work of Andrieu 2022, typical doses of CBD for women with endometriosis range from 25-50 mg per day, divided into 2-3 doses (Front Reprod Health, 2022). For most patients, the starting point is 10 mg in the evening for a week, then increasing by 5-10 mg every 5-7 days. This is the principle of start low, go slow.

The most convenient form is sublingual oil. Drops are applied under the tongue and held for 60-90 seconds before swallowing. The bioavailability of this form is 13-19%, and the first effect appears after 15-45 minutes. A 5% oil (500 mg/10 ml) has about 2.5 mg of CBD per drop, while a 10% oil has about 5 mg per drop. This allows for precise dosing.

A practical regimen for a woman starting with period pain: week 1 – 10 mg in the evening (4 drops of 5%); week 2 – 10 mg in the morning + 10 mg in the evening; week 3 – 15 mg in the morning + 15 mg in the evening; week 4 – maintain and evaluate the effect. If the effect is satisfactory, stay at this dose. If insufficient, consider 10% oil and increase by 10-15 mg each week.

When to increase the dose before menstruation?

Many patients increase their CBD dose 2-3 days before the expected menstruation and maintain it higher for the first 2-3 days of bleeding when pain is strongest. This strategy is called cycle-based dosing. In practice, from 25 mg per day, one approaches 40-50 mg during the perimenstrual period. After menstruation, one returns to the baseline dose.

The strategy makes biological sense because inflammatory activity in endometrial lesions intensifies with menstruation. CB2 receptors on immune cells work more intensively then, so the CBD dose must be adequate. On the other hand, there is a lack of solid clinical evidence for cycle-based dosing, so treat this as an empirical guideline.

Form, frequency, duration

The sublingual form (oils) has the best oral bioavailability and allows for precise dosing. Capsules are more convenient but act slower (60-120 minutes) and less flexibly. Inhalation (vape) acts the fastest, but the effect is short-lived, and we do not recommend it in chronic conditions as a primary route of administration.

Frequency: 2-3 times a day, preferably at regular intervals. CBD has a half-life of 18-32 hours with regular dosing, so blood levels stabilize after 4-7 days. Therefore, the effect is not immediate, and regularity is key.

Duration of treatment: a minimum of 4-8 weeks before assessing the effect. Lack of improvement after 8 weeks despite proper dosing is a signal that CBD is probably not the right strategy for you. Then it is worth discussing alternatives or modifications to the primary therapy with your gynecologist.

dosing guide

What are the safety and interactions of CBD with endometriosis therapy?

CBD is well tolerated in doses up to 1500 mg per day according to a WHO review from 2018. The most common side effects are drowsiness, dry mouth, diarrhea, appetite changes, and mild gastrointestinal disturbances. They occur in 10-20% of users and usually resolve after reducing the dose (WHO, 2018).

The most clinically significant are pharmacokinetic interactions. CBD inhibits cytochrome P450 enzymes, including CYP3A4, CYP2C9, and CYP2C19, which metabolize numerous drugs, including hormones, antiepileptic drugs, statins, SSRIs, and some anticoagulants (PMC, 2019). Hence the requirement for consultation with a physician when combining with medications.

In the context of endometriosis, the most discussed interactions are with hormonal contraception (estrogens, progestogens), dienogest, GnRH agonists, and NSAIDs. The practically significant risk is low with CBD doses up to 50 mg per day, but it increases above 200-300 mg. Therefore, sticking to lower therapeutic doses is a cautious strategy.

CBD and hormonal contraception

Estrogens and progestogens in birth control pills are partially metabolized by CYP3A4. CBD, as an inhibitor of this enzyme, could theoretically increase blood hormone levels and alter their effectiveness. Significant effects are rarely reported in clinical practice, but there are no rigorous pharmacokinetic studies recommending a "safe" dose of CBD alongside contraception.

Practical recommendation: if you are taking a contraceptive pill and introducing CBD, inform your gynecologist. Consider an additional non-pharmacological method of contraception in the first 3 months, especially if the goal is to prevent pregnancy, not just regulate endometriosis. Better safe than sorry.

CBD and dienogest and GnRH

Dienogest (Visanne, Endovelle) is a progestogen used in endometriosis, primarily metabolized by CYP3A4. Combining it with CBD requires caution, although the data is preliminary. GnRH agonists (e.g., Decapeptyl, Lucrin) act centrally, their metabolism is peptide-based, and interactions with CBD are unlikely. This is good news for patients on GnRH.

CBD and NSAIDs

Combining CBD with ibuprofen, naproxen, or ketoprofen is considered safe at typical doses. They act through different mechanisms (NSAIDs through COX, CBD through ECS and TRPV1), so the effect may be additive. Long-term use of high doses of both requires monitoring of the liver and gastrointestinal tract, especially in women with chronic diseases.

CBD and surgery

If you are planning laparoscopy, inform the anesthesiologist about CBD. Some anesthesiology teams recommend discontinuing CBD 7-14 days before the procedure due to potential interactions with anesthetic drugs (propofol, fentanyl, midazolam are P450 substrates). After surgery, return to CBD should be discussed with the lead surgeon, usually after the acute recovery period has passed.

From the editorial experience at u Bucha: Clients' biggest concerns concern interactions with hormonal contraception. We typically refer these individuals to a gynecologist before starting CBD, emphasizing that we cannot replace a medical evaluation. This is a common situation – a woman has been diagnosed with endometriosis, is taking the pill, and the gynecologist encourages "anything that helps," but a specific question about CBD requires a personal conversation.

When does CBD make sense, and when does it NOT?

CBD makes sense as symptomatic support for women with diagnosed endometriosis, managed by a gynecologist, for whom the primary therapy (hormonal or post-surgery) leaves residual pain or sleep issues. In this context, doses of 25-50 mg of CBD per day in the form of broad-spectrum oils may improve quality of life (Front Reprod Health, 2022).

CBD is not a good choice before diagnosis. If you have severe menstrual pain and suspect endometriosis but have not seen a gynecologist, first go to a gynecologist. CBD may mask symptoms and delay diagnosis. The same applies to new alarming symptoms (intermenstrual bleeding, acute abdomen, fever). Diagnosis first, supplementation later.

CBD is also not an option during pregnancy and breastfeeding. The FDA unequivocally advises against CBD during these periods due to a lack of safety data and potential effects on fetal nervous system development (FDA, 2019). Women planning pregnancy should discuss discontinuing CBD with their gynecologist.

Situations where CBD supports treatment

Background pain in endometriosis despite dienogest or other hormonal therapy – here CBD can complement the effect. Sleep disorders associated with nighttime symptoms – an evening dose of 25-50 mg often helps. Anxiety and low mood associated with chronic illness – CBD has a clinically documented anxiolytic effect (Medical Cannabis and Cannabinoids, 2023). Pelvic floor muscle tension – as a complement to physiotherapy.

Situations where CBD is not appropriate

Acute conditions requiring immediate diagnostics (acute abdomen, hemorrhage). Undiagnosed pelvic pain. Pregnancy and breastfeeding. Women with liver diseases (CBD is metabolized hepatically). Patients taking medications with a narrow therapeutic window (e.g., warfarin, some antiepileptic drugs) without strict supervision. Perioperative period without consultation with an anesthesiologist.

How to talk to a gynecologist about CBD?

Prepare a list: what products you use or plan to use, in what doses, for how long, and what you want to achieve. Show certificates of analysis (COAs) for selected oils. Ask directly about interactions with current treatments. Don't hide CBD from your doctor, even if you fear a reaction—withheld information can lead to incorrect treatment decisions.

More and more Polish gynecologists have experience with cannabinoids and are open to discussion. If you encounter a doctor who automatically dismisses the topic, you have the right to seek a second opinion. But also respect medical caution – a doctor is responsible for the patient's safety, and CBD is not yet included in mainstream guidelines as a standard option.

consultation guide

What does collaboration with a gynecologist look like when using CBD?

Collaboration with a gynecologist is the foundation for the safe use of CBD in endometriosis. ESHRE 2022 emphasizes a multifaceted approach to the disease, in which pharmacological treatment, surgery, and symptomatic support are coordinated by a specialist (ESHRE, 2022). CBD is one of the possible elements of symptomatic support, not an alternative to gynecology.

Practically, this looks like this: after diagnosing endometriosis, the gynecologist establishes a basic plan (hormones, possible laparoscopy, monitoring). If the primary therapy is insufficient in the domain of pain, sleep, or mood, discussing CBD is warranted. The doctor can indicate a typical starting dose, frequency of follow-up, and alarm signals requiring discontinuation.

Some gynecologists collaborate with pain medicine doctors who have more experience with cannabinoids. This is a good model because it combines organ expertise (gynecology) with pain expertise (anesthesiology, palliative medicine). In larger urban centers, finding such a team is realistic.

What to document during treatment?

Keep a symptom journal: pain intensity (scale 0-10), sleep quality, days off work due to symptoms, days of your cycle, number of NSAID doses taken. Keeping a journal for three months before and three months during CBD will objectively show the real effect. This provides valuable data for both you and your doctor, and eliminates the "it seems to be helping" trap.

Also record side effects: drowsiness, dry mouth, diarrhea, appetite changes, possibly concentration problems. Most resolve spontaneously, but if they persist, reduce the dose. The gynecologist may also recommend periodic liver tests (ALT, AST) with long-term high-dose treatment.

When to discontinue CBD?

Lack of effect after 8 weeks of proper treatment. The appearance of side effects that do not resolve after reducing the dose. Planned surgery (discontinuation 7-14 days before). Pregnancy or planning pregnancy. Change in primary therapy where the new drug has a narrow therapeutic window. Consult each of these decisions with your doctor, as abrupt discontinuation is not dangerous, but planned is always better.

The ESHRE 2022 guidelines for endometriosis emphasize a multifaceted approach, where hormonal and surgical treatment constitutes the first line, and symptomatic support (including potentially CBD) requires coordination with the leading specialist (ESHRE Endometriosis Guideline, 2022).

How to choose CBD oil for endometriosis?

When choosing CBD oil to support endometriosis, follow three criteria: type of extract (broad or full spectrum), concentration matched to the planned dose, and available certificate of analysis (COA) for each batch. According to Project CBD data, about 78% of Polish customers choose broad-spectrum oils without THC, which is a rational compromise between the entourage effect and safety for THC testing (Project CBD, 2023).

A concentration of 5% (500 mg/10 ml) works well as a start for those just introducing cannabinoids. It allows for precise dosing of 5-25 mg. A concentration of 10% (1000 mg/10 ml) is convenient for dosing 25-50 mg, which is the typical range described in Sinclair 2021 and Andrieu 2022 as symptomatic support for endometriosis.

COA, or certificate of analysis, should include a cannabinoid profile (CBD, CBG, CBN, CBC, THC), terpene profile, and contamination testing (heavy metals, pesticides, solvents, microbiota). A trustworthy manufacturer publishes COA for each production batch, identified by a batch number consistent with the bottle you hold in your hand.

Frequently asked questions about CBD for endometriosis

Does CBD cure endometriosis?

No. CBD does not cure endometriosis and does not reverse endometrial lesions outside the uterus. Endometriosis requires gynecological diagnostics and treatment, including laparoscopy and hormonal therapy, according to the ESHRE guidelines from 2022. CBD can be considered as symptomatic support for pain and sleep quality, after consultation with a gynecologist (ESHRE Guideline, 2022).

What does the Sinclair 2021 study say about CBD and cannabis in endometriosis?

In an online survey published in the Journal of Obstetrics and Gynaecology Canada (Sinclair, 2021) involving 484 women with endometriosis, 95% of respondents declared that cannabis reduced their pain, with the most frequently reported effect being a reduction in symptom severity by about 7.6 points out of 10. However, survey studies have limited evidential power and do not replace randomized clinical trials.

Is CBD safe with hormonal contraception?

CBD inhibits cytochrome P450 enzymes, including CYP3A4 and CYP2C9, which metabolize estrogens and progestogens (PMC, 2019). The clinically significant impact on the effectiveness of contraception is probably small but individually unpredictable. Any combination of CBD with hormonal contraception should be discussed with the treating gynecologist.

What is a typical dose of CBD for pelvic pain related to endometriosis?

In the study by Andrieu 2022 published in Frontiers in Reproductive Health, typical doses of CBD for women with endometriosis ranged from 25-50 mg per day, divided into 2-3 doses (Front Reprod Health, 2022). The start low, go slow protocol recommends starting at 10 mg and increasing every 5-7 days until a satisfactory effect is achieved.

Will CBD replace laparoscopy or hormonal therapy?

No. Laparoscopy remains the gold standard for the diagnosis and surgical treatment of endometriosis, and hormonal therapy (progestogens, GnRH agonists, dienogest) is the first line of pharmacological treatment (ESHRE Guideline, 2022). CBD does not remove endometrial lesions nor does it inhibit their growth in a way that would replace gynecology. It is symptomatic support, not causal therapy.

Is the endocannabinoid system disrupted in endometriosis?

Yes. Reviews involving Barlow 2018 and Sanchez Quesada 2018 have shown changes in the expression of CB1 and CB2 receptors in the endometrium of patients with endometriosis, including reduced CB1 expression in deep lesions (Reprod Sci, 2018; Mol Cell Endocrinol, 2018). This suggests ECS dysfunction as an element of pathogenesis, although it is not a confirmed causal relationship.

How long do you have to wait for the effect of CBD in endometriosis?

The first symptomatic effects (e.g., better sleep, reduced tension) may be felt after 1-2 weeks. The full anti-inflammatory effect usually requires 4-8 weeks of regular dosing, similar to studies on other chronic pain syndromes (Reinert, 2023). Lack of effect after 8 weeks justifies changing the strategy and consulting with a doctor.

Does CBD affect fertility and pregnancy planning?

Data is insufficient. Studies in animal models suggest that ECS regulates embryo implantation and decidualization, so CBD modulation may not be neutral (Barlow, 2018). The FDA unequivocally advises against CBD during pregnancy and breastfeeding (FDA, 2019). Women planning pregnancy should discuss CBD with their gynecologist before becoming pregnant.

Can I combine CBD with NSAID painkillers?

Yes, combining CBD with NSAIDs (ibuprofen, naproxen) at typical doses is considered safe, as they act through different mechanisms. CBD and NSAIDs may synergistically reduce inflammation. However, long-term use of high doses of both requires monitoring of the liver and gastrointestinal tract, preferably under the supervision of the treating physician.

When is CBD not a good choice for endometriosis?

CBD is not a good choice when pelvic pain has features of acute abdomen, when there is intermenstrual bleeding, during pregnancy and breastfeeding, during therapy with drugs metabolized by CYP3A4 without medical supervision, and before planned surgery. In these situations, the priority is urgent gynecological consultation, not cannabinoid supplementation.

Summary and what next

Endometriosis remains a diagnostic and therapeutic challenge. The average delay in diagnosis is 7-10 years, the lack of effective causal therapy, and often incomplete response to hormones lead patients to seek symptomatic support. CBD is one of the options that scientifically make sense. ECS is active in the endometrium, modulation of CB1/CB2 receptors and inhibition of inflammation is a coherent mechanism of action.

Clinical data is promising but preliminary. Sinclair 2021, Andrieu 2022, and Reinert 2023 consistently indicate potential but lack large-scale randomized clinical trials. Therefore, CBD remains off-label support, not a standard of care. Typical doses are 25-50 mg per day in the form of broad-spectrum oils, divided into 2-3 doses.

The most important principle: CBD does not replace a gynecologist, laparoscopy, or hormonal therapy. It is one of the possible elements of the treatment plan, coordinated with the treating physician. If you are considering CBD for diagnosed endometriosis, discuss it with your gynecologist. If you do not yet have a diagnosis, first go to a specialist; supplementation can wait.

Endometriosis is serious, but it is also well recognized in Poland in 2026. More and more centers offer comprehensive treatment, urogynecological physiotherapy, psychological support, and open discussions about natural adjunctive methods. You are not alone with this disease, and you have the right to seek a competent medical team that understands you.

This article is informational and educational and does not constitute medical advice. Endometriosis is a serious disease requiring diagnostics and management by a gynecologist. CBD does not cure endometriosis and does not replace hormonal or surgical therapy. Before starting CBD, consult with your treating physician, especially if you are using hormonal contraception, dienogest, GnRH agonists, planning pregnancy, or are pregnant or breastfeeding.

Sources:

• ESHRE. Endometriosis Guideline. https://www.eshre.eu/, 2022.
• Sinclair J. et al. Cannabis use, a self-management strategy among Australian women with endometriosis. J Obstet Gynaecol Can, 2021.
• Andrieu T. et al. Cannabinoids in endometriosis. Frontiers in Reproductive Health, 2022.
• Reinert J. et al. Cannabinoids in chronic pelvic pain. PubMed, 2023.
• Barlow D. et al. Endocannabinoid system in the endometrium. Reproductive Sciences, 2018.
• Sanchez Quesada A. et al. Endocannabinoid receptors in endometriosis. Mol Cell Endocrinol, 2018.
• FDA. CBD use during pregnancy and breastfeeding. FDA, 2019.
• WHO. Cannabidiol pre-review report. World Health Organization, 2018.
• FDA. Epidiolex prescribing information. FDA, 2018.

Author: Michał Waluk, Editor of the Bucha blog
Publication date: April 26, 2026
Next update: April 26, 2027